Dr Reddy's may file two new drugs with FDA by 2019

Drug maker Dr Reddy's Laboratories Limited has said that it is currently working on 16 new drug applications and out of which a drug to treat migraines has completed Phase-3 trials and another anti-cancer biologic agent is currently under Phase-3 trials. 

According to filing with the US Securities and Exchange Commission, the city-based pharma company is expected to file the New Drug Application (NDA) with US Food and Drug Administration with regard the migraine drug in 2018 while it  is expected to submit license application for the cancer drug, it may approach the drug regulator in 2019. 

"As of March 31, 2017, we had 16 active product development programs in our pipeline (for DFN-02- the drug to treat acute treatment of migraines, with or without aura in adults) Phase 3 is completed. Submission of NDA to USFDA is planned for 2018," it said. 

Another (E7777-Treatment of Cutaneous T Cell Lymphoma) is an anti-cancer biologic agent in-licensed from EISAI limited...Phase 3 is in process. Submission of a biologics license application to the USFDA is planned for 2019," the company said. 

It however, said the timelines for expected filing may change due to various factors including outcome of Phase 3 studies, completion of Integrated Summary of Safety/Integrated Summary of effectiveness outcome of stability data and internal reprioritization of portfolio. 


The company's principal research and development facilities are located in Telangana-India, Cambridge-United Kingdom and Leiden- the Netherlands while the principal manufacturing facilities are located in Telangana, Andhra Pradesh and Himachal Pradesh in India, Cuernavaca-Cuautla, Mexico, Mirfield, United Kingdom, Louisiana and Tennessee, United States. 

The research and development expenses of the drugmaker were at Rs 1955 crore for the year ended March 31, 2017, an increase of 10 per cent as compared to Rs 1783.4 crore during FY 16. 


"This increase was in accordance with our strategy to expand our research and development efforts in complex formulations, differentiated formulations and bio-similar compounds," the company said in the filing.


Source:http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-may-file-two-new-drugs-with-fda-by-2019/articleshow/59233360.cms

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more